Biomarkers in Breast CancerGiampietro Gasparini, Daniel F. Hayes Springer Science & Business Media, 2008 M01 17 - 342 páginas Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. |
Contenido
3 | |
Analytical Aspects of Biomarker Immunoassays | 17 |
State of the Art Pitfalls and Promises | 31 |
Assays for Gene Expression and PostTranslational | 45 |
State of the Art Pitfalls | 65 |
Cell Kinetics | 81 |
and Chemotherapy in Breast Cancer | 129 |
The Epidermal Growth Factor Receptor Pathway as a Selective | 177 |
p53 as a Prognostic and Predictive Indicator | 193 |
Predictive Biomarkers in Body Fluids | 211 |
Clinical Utility | 235 |
Detection of Early Tumor Dissemination in Patients | 293 |
New TechnologiesNew MarkersNew Challenges | 325 |
333 | |
Otras ediciones - Ver todas
Términos y frases comunes
activity adjuvant amplification analysis antibody assay assessment associated biological biomarker block blood bone marrow breast cancer cells breast cancer patients Cancer Res carcinoma changes chemotherapy circulating Clin Oncol clinical combination compared correlated demonstrated detection determination disease effect elevated endothelial et al evaluation expression FISH gene growth factor HER2 HER2/neu Herceptin hormone human human breast identify important increased indices inhibitor laboratories levels lines lymph node marker measured metastatic breast cancer methods microarray molecular negative node-negative normal occult Oncology outcome overall overexpression performed phase positive predictive presence primary prognostic progression proliferation prospective protein received receptor REFERENCES reported response risk role samples selection sensitivity serum showed signaling significance specific stage standard status studies suggest systemic Table tamoxifen therapy tissue trastuzumab treated treatment trial tumor cells vascular VEGF women